Drug Database
SC

Scherersol delivery systems (Polysol / Quadrisol / Cosol)

✓ Approved

Cardinal Health, Inc. · Small Molecule · Small Molecule

What is Scherersol delivery systems?

Scherersol delivery systems is a small molecule developed by Cardinal Health, Inc.. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesPolysol, Quadrisol, Cosol
CompanyCardinal Health, Inc.
Drug ClassSmall Molecule
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Cardinal Health, Inc.

Therapeutic Indications

Scherersol delivery systems is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Surgical and medical proceduresOral appliance application✓ Approved

Related Research Articles

PubMedAAPS PharmSciTech2026-10-16

Polymer-based Vaginal Insert Systems: Engineering Controlled Drug Delivery for Women's Health.

Kadam Shruti S, Dabhoya Mansvi M, Patel Riya R, Shah Shreeraj S

Polymer-based vaginal inserts have emerged as a promising approach for localized and systemic drug delivery, demonstrating improved therapeutic efficacy, prolonged drug residence, controlled release and enhanced patient compliance compared to conventional vaginal dosage forms. This article gives a complete overview of the design and development of polymer-based vaginal inserts, covering the influence of vaginal physiology, mucoadhesion and polymer selection on formulation performance. The properties and applications of natural, synthetic, and hybrid polymers, and current breakthroughs in fabrication technologies such as freeze-drying, solvent casting, hot-melt extrusion, electrospinning, and 3D printing are covered. Also examined are several drug release techniques such as sustained, swelling-controlled, stimuli-responsive and mucoadhesive systems. Moreover, the therapeutic potential of vaginal inserts for the treatment of vulvovaginal infections, endometriosis, cervical cancer, uterine fibroids, menopause-related illnesses, contraception and HIV prevention is emphasized. Finally, the future directions of emerging technologies, such as nanotechnology, smart polymers, artificial intelligence, and personalized drug delivery systems, are discussed for the clinical translation and enhanced efficacy of polymer-based vaginal drug delivery systems for women's reproductive health.

PMID 42881338
Read full article →
PubMedInternational journal of molecular sciences2026-10-16

Advanced Drug Delivery in Pediatric Neurology: Developmental Barriers, Nanocarrier Strategies, and Translational Challenges.

Teleanu Raluca Ioana RI, Bratu Andreea Gabriela AG, Niculescu Adelina-Gabriela AG, Perjoc Radu Ștefan RȘ et al.

Treating neurological disorders in children is particularly challenging due to the dynamic maturation of the developing brain, age-dependent pharmacokinetics, and evolving structural and functional properties of the blood-brain barrier (BBB). This review explores the latest advances in drug-delivery systems tailored for pediatric neurology, emphasizing strategies to address physiological and developmental determinants of treatment response across infancy, childhood, and adolescence. The paper begins by outlining the distinct challenges of drug delivery in children, focusing on BBB maturation, transporter expression, metabolic capacity, and neurodevelopmental vulnerability. Emerging delivery systems, such as liposomes, polymeric nanoparticles, dendrimers, micelles, gold nanoparticles, and gene- and RNA-based vectors, are further reviewed in relation to major pediatric neurological conditions. These platforms demonstrate promise in enhancing drug bioavailability, targeting specific brain regions, and minimizing systemic toxicity. This paper also covers important safety, regulatory, and ethical considerations in pediatric populations, with a focus on the need for age-appropriate design and thorough clinical validation. Concluding with emerging trends and future directions, this work serves as a comprehensive resource for advancing pediatric neurological therapeutics through state-of-the-art drug delivery technologies.

PMID 42883972
Read full article →
PubMedPolymers2026-10-16

Hydrogel-Based BMP-2 Delivery for Bone Regeneration: From Material Control to Biological and Translational Evaluation.

Zhou Tingting T, He Xian X, Li Jiahe J, Han Xianglong X et al.

Bone morphogenetic protein-2 (BMP-2) is a potent osteoinductive factor, but rapid loss of bioactivity, short local retention, burst release, and diffusion into surrounding tissues reduce dose efficiency and may necessitate supraphysiological doses associated with local adverse effects. Hydrogels offer tunable platforms for controlling BMP-2 localization, exposure, and presentation. This review classifies BMP-2-delivering hydrogels by their dominant delivery logic into passive spatial confinement, reservoir-unit-integrated delivery, stimuli-responsive delivery, and programmable biointeractive systems. It then evaluates whether material-level control translates into retained bioactivity, cellular responses, bone regeneration, spatially confined bone formation, and clinically relevant outcomes across conventional and complex-host models. Selected systems preserve BMP-2 activity after chemical modification, immobilization, or triggered release and improve bone formation, structural repair, or spatial localization in specific models. Nevertheless, prolonged retention or greater material complexity does not consistently improve repair, and evidence for true dose sparing remains limited. Outcomes depend on actual bioactive exposure, material degradation, tissue ingrowth, host conditions, and auxiliary components. Translation therefore requires formulation-specific links among dose, bioactive exposure, repair efficacy, local safety, and reproducible manufacturing.

PMID 42884980
Read full article →
PubMedMolecules (Basel, Switzerland)2026-10-16

Recent Advances in Small-Molecule-Based Nanovectors for the Treatment of Colorectal Cancer.

Kibungu Cuthbert Wasswa CW, Mongalo Nkoana Ishmael NI, Makhafola Tshepiso Jan TJ

Colorectal cancer (CRC) remains a major global health burden, while conventional systemic therapies are limited by toxicity, drug resistance, suboptimal tumour exposure, and pharmacokinetic constraints. Recent advances in nanotechnology have produced diverse nanosystems including liposomes, dendrimers, polymeric nanoparticles, metallic nanoparticles, mesoporous silica systems, and other hybrid platforms that can improve drug solubility, stability, biodistribution, controlled release, and tumour-directed delivery. Plant-derived small molecules provide an additional source of structurally diverse anticancer candidates, but their clinical development is often constrained by poor aqueous solubility, rapid metabolism, limited bioavailability, and non-specific toxicity. This review critically examines recent progress in nanoscale delivery systems for CRC and evaluates their potential for delivering plant-derived and other bioactive small molecules. Particular emphasis is placed on passive and active targeting, physicochemical determinants of delivery, platform-specific advantages and limitations, preclinical evidence, and the barriers to clinical translation. The review also highlights the distinction between plant-derived and fungal-derived natural products and identifies opportunities for integrating natural products with responsive and ligand-functionalized nanocarriers.

PMID 42883298
Read full article →
PubMedMolecules (Basel, Switzerland)2026-10-16

Reimagining Cannabidiol Delivery Through Carbon Nanodots.

Ibrahim Iddrisu I, Lawrence Kelci K, Forte Othreniel Angel OA, Naidu Navitri Chandra NC et al.

Cannabidiol (CBD) is a highly lipophilic phytocannabinoid whose low aqueous solubility, variable oral absorption, extensive first-pass metabolism, and chemical instability motivate advanced delivery strategies. Carbon nanodots (CNDs) have tunable surface chemistry and photoluminescence and have been investigated as carriers for multiple therapeutic cargos. This review critically evaluates whether the literature supports a specific CBD-CND delivery advantage. A structured narrative search of PubMed and targeted publisher websites was conducted. Evidence was classified as direct CBD-CND evidence, indirect CND-platform evidence, or indirect CBD-nanoformulation evidence. No direct study was identified that characterized CBD loading on CNDs and then demonstrated release, pharmacokinetics, safety, or therapeutic efficacy. Existing support is therefore indirect: CNDs can carry other drugs, whereas lipid, polymeric, micellar, and transdermal systems can improve selected CBD formulation or preclinical endpoints. Consequently, improved solubility, targeting, lower toxicity, enhanced bioavailability, and therapeutic synergy remain hypotheses for CBD-CND systems. The review retains a broad discussion of possible applications while clearly separating demonstrated evidence from proposed uses and defining the analytical, comparative, pharmacokinetic, biodistribution, and toxicological studies needed to validate the platform.

PMID 42883170
Read full article →
PubMedNutrients2026-10-16

Operationalising the Operational Guidance on Infant and Young Child Feeding in Emergencies: A Narrative Review of Implementation Strategies, Barriers, Facilitators, and Health System Integration in Humanitarian Settings.

Mphasha Mabitsela Hezekiel MH, Mphasha Elisa Sebina ES, Vagiri Rajesh R

Background: Humanitarian emergencies disrupt infant and young child feeding (IYCF), weaken health systems, and increase risks of malnutrition, morbidity, and mortality. Although the Operational Guidance on the Infant and Young Child Feeding in Emergencies (OG-IFE) provides a global framework for protecting optimal feeding practices, its translation into practice remains inconsistent. This review examines the operationalisation of OG-IFE within humanitarian health and nutrition systems. Methods: A structured narrative review synthesised evidence on OG-IFE operationalisation. Seven databases were searched for peer-reviewed and grey literature (2017-2026). PRISMA-informed screening identified 66 eligible sources. Data were systematically extracted and analysed using inductive thematic synthesis, generating ten themes addressing barriers, facilitators, governance, coordination, service delivery, and system-level approaches to implementing OG-IFE across humanitarian settings. Results: Effective operationalisation depends on integrated systems rather than isolated interventions. Key enablers include institutionalisation within health and emergency systems, multisectoral coordination, trained workforces, community-based delivery platforms, and evidence-informed innovations. Barriers include weak health systems, fragmented coordination, limited financing, sociocultural and gender constraints, inappropriate breastmilk substitute practices, and weak monitoring and accountability systems. Conclusions: The review found that operationalisation of the OG-IFE is constrained more by health and humanitarian system weaknesses than by technical guidance. Effective operationalisation depends on coherent governance, preparedness, financing, workforce capacity, monitoring, regulation, and community engagement. While breastfeeding support is relatively well operationalised, major gaps remain in support for non-breastfed infants and other system domains, highlighting the need for integrated, systems-based approaches.

PMID 42884652
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about Scherersol delivery systems